

Issued by JPAC: 31 May 2022

Implementation: To be determined by each Service


Change Notification UK National Blood Services No. 36 - 2022

Clopidogrel

These changes apply to the Bone Marrow and Peripheral Stem Cell Donor Selection Guidelines.

This is a new entry.

| | |
|-------------------------------|---|
| <i>Obligatory</i> | Must not donate |
| <i>Discretionary</i> | If prescribed for primary prevention of cardiovascular disease, discuss with DCSO |
| <i>Additional Information</i> | <p>Clopidogrel is an antiplatelet drug which is used in the treatment and secondary prevention of cardiovascular disease and stroke. In this case, the underlying condition would be a contraindication to donation, in the interests of donor safety.</p> <p>Occasionally Clopidogrel is used for primary prevention in patients who are intolerant of or hypersensitive to aspirin. Donor needs to be assessed by DCSO for the suitability of withholding clopidogrel for the relevant procedure.</p> |
| <i>Reason for change</i> | This is a new entry. |



Dr Stephen Thomas
Professional Director - Joint UKBTS Professional Advisory Committee
✉ stephen.thomas@nhsbt.nhs.uk